Bio Green Med Solution, Inc.
BGMSHealthcare|Medical - Pharmaceuticals|MY
$0.86
-0.01 (-0.58%)
DCF Value
$4.74
Tangible Book / Share
$1.00
Cash / Share
$0.68
Financials
Financial Snapshot
Market Cap
$4.7M
Enterprise Value
$956.7K
Revenue (TTM)
$1.9M
Net Income (TTM)
-$2.2M
Cash & Investments
$3.8M
Net Cash
$3.8M
Free Cash Flow (TTM)
-$1.1M
Operating CF (TTM)
-$1.1M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$3.8M
Quarterly Burn
$274.3K
Monthly Burn
$91.4K
Est. Runway
~13.8 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $16.7M | $24.0M | $17.5M | $11.9M | $33.4M | $36.6M | $18.3M | $3.4M | $3.1M | $3.5M | $3.8M | |
| Operating Cash Flow | -$10.1M | -$7.5M | -$6.7M | -$9.4M | -$7.9M | -$18.5M | -$20.8M | -$16.1M | -$8.0M | -$4.8M | -$1.1M | |
| Free Cash Flow | -$10.1M | -$7.5M | -$6.7M | -$9.5M | -$8.0M | -$18.6M | -$20.8M | -$16.1M | -$8.0M | -$4.8M | -$1.1M | |
| Capital Expenditure | -$3.0K | -$13.0K | -$39.0K | -$10.0K | -$96.0K | -$27.0K | -$7.0K | -$6.0K | $0.00 | $0.00 | -$1.0K | |
| Financing Cash Flow | $6.6M | $14.7M | $429.0K | $3.8M | $29.5M | $21.7M | $3.0M | $848.0K | $7.8M | $5.3M | $616.0K |
R&D Spending
R&D (TTM)
-$43.0K
R&D Intensity
-2.3%
R&D Growth vs Prior
-105.1%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $843.0K | $0.00 | $150.0K | $0.00 | $0.00 | $0.00 | $0.00 | $420.0K | $43.0K | $747.0K | $1.9M | |
| R&D Expense | $9.5M | $4.2M | $4.3M | $4.7M | $4.7M | $14.9M | $20.3M | $19.2M | $6.7M | $848.0K | -$43.0K | |
| R&D % of Revenue | 1124.2% | — | 2884.7% | — | — | — | — | 4560.7% | 15476.7% | 113.5% | -2.3% | |
| SG&A | $5.5M | $5.3M | $5.4M | $5.0M | $5.9M | $7.5M | $7.4M | $6.7M | $5.4M | $7.7M | $3.1M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $843.0K | $0.00 | $150.0K | $0.00 | $0.00 | $0.00 | $0.00 | $420.0K | $43.0K | $747.0K | $1.9M | |
| Cost of Revenue | $9.5M | $4.2M | $4.3M | $4.7M | $20.0K | $43.0K | $32.0K | $0.00 | $0.00 | $609.0K | $1.5M | |
| Gross Profit | -$8.6M | -$4.2M | -$4.2M | -$4.7M | -$20.0K | -$43.0K | -$32.0K | $420.0K | $43.0K | $138.0K | $360.0K | |
| R&D | $9.5M | $4.2M | $4.3M | $4.7M | $4.7M | $14.9M | $20.3M | $19.2M | $6.7M | $848.0K | -$43.0K | |
| SG&A | $5.5M | $5.3M | $5.4M | $5.0M | $5.9M | $7.5M | $7.4M | $6.7M | $5.4M | $7.7M | $3.1M | |
| Operating Income | -$14.2M | -$9.5M | -$9.5M | -$9.7M | -$10.6M | -$22.4M | -$27.7M | -$25.5M | -$12.0M | -$8.4M | -$2.7M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$13.8M | -$8.5M | -$8.6M | -$9.1M | -$9.7M | -$22.2M | -$25.9M | -$25.6M | -$12.0M | -$3.0M | -$2.2M | |
| Net Income | -$11.8M | -$7.5M | -$7.3M | -$7.8M | -$8.4M | -$18.5M | -$21.2M | -$22.6M | -$11.2M | -$3.0M | -$2.2M | |
| EPS (Diluted) | -252000.00 | -140400.00 | -44584.00 | -35426.00 | -12306.00 | -7704.00 | -6840.00 | -6420.00 | -501.60 | -6.45 | -3.64 | |
| EBITDA | -$14.0M | -$9.5M | -$9.5M | -$9.7M | -$9.7M | -$22.3M | -$27.6M | -$25.4M | -$12.0M | -$8.4M | -$2.7M | |
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 2.19 | 5.60 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $16.5M | $23.9M | $17.5M | $11.9M | $33.4M | $36.6M | $18.3M | $3.4M | $3.1M | $3.5M | $3.8M | |
| Short-Term Investments | $132.0K | $132.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $19.6M | $26.0M | $19.8M | $14.0M | $35.5M | $40.9M | $24.4M | $7.4M | $3.7M | $6.3M | $6.0M | |
| Total Assets | $19.7M | $26.0M | $19.8M | $15.3M | $36.8M | $43.1M | $28.1M | $8.8M | $4.1M | $8.2M | $7.9M | |
| Total Current Liabilities | $5.3M | $4.1M | $4.5M | $2.4M | $2.5M | $5.4M | $7.5M | $8.2M | $6.3M | $1.3M | $692.0K | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $5.4M | $4.2M | $4.6M | $3.6M | $3.5M | $5.4M | $7.6M | $8.2M | $6.3M | $1.3M | $694.0K | |
| Stockholders' Equity | $14.3M | $21.8M | $15.3M | $11.7M | $33.3M | $37.7M | $20.4M | $607.0K | -$2.2M | $6.8M | $7.2M | |
| Retained Earnings | -$335.0M | -$342.5M | -$349.8M | -$357.6M | -$366.1M | -$384.5M | -$405.7M | -$428.3M | -$439.5M | -$454.4M | -$455.0M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$10.1M | -$7.5M | -$6.7M | -$9.4M | -$7.9M | -$18.5M | -$20.8M | -$16.1M | -$8.0M | -$4.8M | -$1.1M | |
| Capital Expenditure | -$3.0K | -$13.0K | -$39.0K | -$10.0K | -$96.0K | -$27.0K | -$7.0K | -$6.0K | $0.00 | $0.00 | -$1.0K | |
| Free Cash Flow | -$10.1M | -$7.5M | -$6.7M | -$9.5M | -$8.0M | -$18.6M | -$20.8M | -$16.1M | -$8.0M | -$4.8M | -$1.1M | |
| Investing Cash Flow | $9.0K | -$13.0K | -$39.0K | $28.0K | -$96.0K | -$27.0K | -$7.0K | -$6.0K | $0.00 | $0.00 | -$1.0K | |
| Financing Cash Flow | $6.6M | $14.7M | $429.0K | $3.8M | $29.5M | $21.7M | $3.0M | $848.0K | $7.8M | $5.3M | $616.0K | |
| Issuance of Stock | $6.8M | $14.9M | $630.0K | $4.0M | $29.7M | $21.9M | $3.2M | $1.0M | $6.2M | $6.4M | $1.8M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $782.0K | $266.0K | $331.0K | $466.0K | $430.0K | $1.2M | $1.5M | $1.5M | $592.0K | $2.3M | $662.0K | |
| Net Change in Cash | -$3.9M | $7.4M | -$6.4M | -$5.6M | $21.5M | $3.2M | -$18.2M | -$15.0M | -$241.0K | $368.0K | -$485.0K |
Dilution Tracker
Shares outstanding grew 216458.5% over 5 years — significant dilution
Shares Outstanding
6M
5-Year Share Growth
+216458.5%
Stock Issuance (TTM)
$1.8M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 2.19 | 5.60 | |
| Change vs Prior % | — | 120.8% | 58.5% | 35.1% | 344.5% | 145.7% | 26.1% | 13.4% | 941.3% | 5819.5% | 156.2% | |
| Stock Issuance | $6.8M | $14.9M | $630.0K | $4.0M | $29.7M | $21.9M | $3.2M | $1.0M | $6.2M | $6.4M | $1.8M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $782.0K | $266.0K | $331.0K | $466.0K | $430.0K | $1.2M | $1.5M | $1.5M | $592.0K | $2.3M | $662.0K |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | -1024.2% | — | -2784.7% | — | — | — | — | 100.0% | 100.0% | 18.5% | 19.3% | |
| Operating Margin % | -1678.5% | — | -6365.3% | — | — | — | — | -6060.2% | -27916.3% | -1128.1% | -147.1% | |
| Net Margin % | -1398.7% | — | -4858.7% | — | — | — | — | -5370.2% | -26074.4% | -401.3% | -118.3% | |
| EBITDA Margin % | -1662.8% | — | -6346.0% | — | — | — | — | -6052.9% | -27902.3% | -1127.4% | -146.7% | |
| FCF Margin % | -1196.0% | — | -4493.3% | — | — | — | — | -3837.6% | -18581.4% | -638.6% | -59.0% | |
| ROE % | -82.6% | -34.3% | -47.7% | -66.9% | -25.4% | -49.0% | -103.7% | -3715.8% | 515.7% | -43.8% | -31.6% | |
| ROA % | -60.0% | -28.7% | -36.8% | -51.1% | -22.9% | -42.8% | -75.6% | -256.2% | -273.9% | -36.6% | -28.0% | |
| ROIC % | -98.2% | -43.4% | -62.1% | -75.1% | -27.0% | -49.4% | -110.1% | -3488.9% | 515.9% | -123.0% | -38.2% | |
| R&D / Revenue % | 1124.2% | — | 2884.7% | — | — | — | — | 4560.7% | 15476.7% | 113.5% | -2.3% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -56.6% | -100.0% | 0.0% | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | -89.8% | 1637.2% | |
| Gross Profit | 17.3% | 50.9% | 1.4% | -11.5% | 99.6% | -115.0% | 25.6% | 1412.5% | -89.8% | 220.9% | |
| Operating Income | 12.5% | 32.9% | -0.6% | -1.4% | -9.9% | -110.5% | -23.5% | 8.0% | 52.8% | 29.8% | |
| Net Income | 17.8% | 36.6% | 2.4% | -7.4% | -7.9% | -118.6% | -14.9% | -6.4% | 50.3% | 73.3% | |
| EPS (Diluted) | 35.2% | 44.3% | 68.2% | 20.5% | 65.3% | 37.4% | 11.2% | 6.1% | 92.2% | 98.7% | |
| Operating Cash Flow | 30.3% | 25.8% | 10.4% | -41.0% | 16.0% | -133.7% | -12.3% | 22.6% | 50.4% | 40.3% | |
| Free Cash Flow | 30.4% | 25.7% | 10.0% | -40.3% | 15.1% | -131.2% | -12.2% | 22.6% | 50.4% | 40.3% | |
| R&D Expense | -23.5% | -55.3% | 2.1% | 7.6% | 1.7% | 215.0% | 35.8% | -5.5% | -65.3% | -87.3% | |
| SG&A Expense | -3.8% | -4.7% | 2.2% | -6.5% | 17.0% | 27.0% | -1.1% | -9.0% | -19.7% | 43.1% | |
| Total Assets | -20.6% | 32.3% | -23.8% | -22.8% | 140.4% | 17.2% | -35.0% | -68.6% | -53.5% | 99.9% | |
| Book Value / Share | -40.0% | -30.9% | -55.7% | -43.3% | -36.0% | -53.9% | -57.0% | -97.4% | -134.4% | 105.3% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | -11.3% | -97.2% | 253.3% | -65.1% | -100.0% | 0.0% | |
| Diluted Shares | 26.3% | 120.8% | 58.5% | 35.1% | 344.5% | 145.7% | 26.1% | 13.4% | 941.3% | 5819.5% |
Valuation
P/E (TTM)At Loss
P/S2.55
10Y Low / Med / High0.00 / 0.05 / 5.17
P/B0.67
10Y Low / Med / High0.00 / 0.00 / 0.47
EV/EBITDAAt Loss
10Y Low / Med / High0.03 / 1.18 / 3.35
EV/Revenue0.51
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$4.74
Tangible Book / Share
$1.00
Net Current Assets / Share
$0.96
Graham Net-Net
$0.78
Cash / Share
$0.68
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.01 | -0.23 | -0.24 | |
| P/S Ratio | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 5.17 | 4.33 | 2.55 | |
| P/B Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | -0.10 | 0.47 | 0.67 | |
| EV/EBITDA | 1.18 | 2.53 | 1.84 | 1.11 | 3.35 | 1.63 | 0.66 | 0.13 | 0.24 | 0.03 | -0.35 | |
| EV/Revenue | -19.60 | 0.00 | -116.69 | 0.00 | 0.00 | 0.00 | 0.00 | -7.90 | -67.79 | -0.36 | 0.51 |
Analyst Estimates & Quality
Altman Z-Score
-77.11
Distress
Piotroski F-Score
4
Moderate
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $100.0K | $80.6M | $118.1M |
| Net Income | -$587.3M | $1.92B | $2.88B |
| EPS | $-268.80 | $880.80 | $1317.60 |
| # Analysts (EPS) | 1 | 1 | 1 |
Dividends
Frequency
Irregular
Recent Payments
| Ex-Date | Pay Date | Amount | Frequency |
|---|---|---|---|
| Apr 29, 2025 | $36.00 | Irregular |